Last reviewed · How we verify
NCT05067881: PHC
Post-COVID-19 Pneumo-hematocele
trial testing Pulmonary resection in COVID-19 Respiratory Infection in 37 participants. Completed in 20 September 2021.
1 March 2020
Quick facts
| Lead sponsor | Hospital General Ajusco Medio |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 37 |
| Start date | 1 March 2020 |
| Primary completion | 1 March 2020 |
| Estimated completion | 20 September 2021 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Pulmonary resection
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
Sponsor
Hospital General Ajusco Medio
Who can join
Adults 18 to 80, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction. As the COVID-19 pandemic has continued, an increasing number of long-term complications are emerging. Recently, the appearance of characteristic pulmonary lesions has been noted, being described as post COVID-19 pneumatocele. The aim of this study is to describe the clinical, histopathologic and imaging features of post COVID-19 pneumo-hematoceles (PHC) and secondarily to suggest a treatment algorithm in these patients. Methods. A retrospective study was performed in patients admitted with diagnosis of SARS-CoV2 infection from March 2020 to September 2021 who presented PHC on imaging studies. Clinical and demographic variables were recorded and CT scans were analyzed. A logistic regression analysis was performed to determine the risk for rupture according to PHC characteristics. It appears that PHC occurs secondary to encapsulation of blood accumulation, the result of micro capillary bleeding, with partial reabsorption of blood and subsequent air filling. The recommendation is to operate on patients with PHC of 5cm and those with persistent lesions of 3cm.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Post COVID-19 pneumo-hematocele: clinical presentation and treatment pathway.
Chávez KV, Pimienta-Ibarra AS, Máruquez-González H, Flores-Garcés JC, et al · · 2022 · cited 4× · PMID 35041128 · DOI 10.1007/s11748-022-01771-0
Verify or expand the search:
- PubMed search for NCT05067881
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other Hospital General Ajusco Medio trials
Trials by the same sponsor.
- NCT04859881 — Risk Factors for Barotrauma in COVID-19 · completed
- NCT03345368 — Effect of rTMS in Combination With a Low-carbohydrate Diet in Patients With Obesity · NA · completed
- NCT04484116 — IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism · completed
- NCT05696405 — VATS for Resection of Mediastinal Parathyroids · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05067881 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General Ajusco Medio
- Last refreshed: 5 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05067881.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing